Ustekinumab May Trigger Acute CV Events Early in Treatment Ustekinumab May Trigger Acute CV Events Early in Treatment

Initiating treatment with ustekinumab, an IL-12/23-targeting monoclonal antibody, may trigger early severe cardiovascular events in susceptible patients.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news